Companies › Phathom Pharmaceuticals
1 active drug program in 22 registered trials: 14 Phase 4, 4 Phase 2, 3 Phase 3, 1 Phase 1; Cardiovascular, Gastroenterology, Genitourinary, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vonoprazan Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Symptomatic Non-erosive Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer; HELICOBACTER PYLORI INFECTIONS … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07068607 | Vonoprazan | Phase 4 | Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer | Oncology | Oct 2025 |
| NCT06723197 | Vonoprazan | Phase 4 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Oct 2025 |
| NCT06723197 | Vonoprazan | Phase 4 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Oct 2025 |
| NCT07267260 | Vonoprazan | Phase 2 | Cirrhoses, Liver | Cardiovascular | Jan 2026 |
| NCT06959368 | Vonoprazan | Phase 4 | Helicobacter Pylori Infection | Infectious disease | Mar 2026 |
| NCT07344506 | Vonoprazan | Phase 4 | H. Pylori Gastrointestinal Disease | Infectious disease | May 2026 |
| NCT06564246 | Vonoprazan | Phase 4 | Gastroesophageal Reflux Disease (GERD) | Gastroenterology | Aug 2026 |
| NCT05957432 | Vonoprazan | Phase 2 | Helicobacter Pylori Infection | Infectious disease | Nov 2026 |
| NCT06929962 | Vonoprazan | Phase 4 | Helicobacter Pylori Infection | Infectious disease | Dec 2026 |
| NCT06851559 | Vonoprazan | Phase 2 | Eosinophilic Esophagitis | Gastroenterology | Dec 2026 |
| NCT04713670 | Vonoprazan | Phase 4 | H. Pylori Infection | Infectious disease | Dec 2026 |
| NCT04713670 | Vonoprazan | Phase 4 | H. Pylori Infection | Infectious disease | Dec 2026 |
| NCT04713670 | Vonoprazan | Phase 4 | H. Pylori Infection | Infectious disease | Dec 2026 |
| NCT04713670 | Vonoprazan | Phase 4 | H. Pylori Infection | Infectious disease | Dec 2026 |
| NCT07275827 | Vonoprazan | Phase 3 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Dec 2026 |
| NCT07293910 | Vonoprazan | Phase 2 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Dec 2026 |
| NCT07275632 | Vonoprazan | Phase 1 | Delayed Graft Function | Genitourinary | Dec 2026 |
| NCT07752407 | Vonoprazan | Phase 3 | Symptomatic Non-erosive Gastroesophageal Reflux Disease | Gastroenterology | Oct 2027 |
| NCT05582174 | Vonoprazan | Phase 4 | Upper GI Bleeding | Gastroenterology | Jan 2028 |
| NCT07788742 | Vonoprazan | Phase 4 | Barrett Esophagus | Gastroenterology | Aug 2028 |
| NCT06526455 | Vonoprazan | Phase 4 | Ulcers, Gastric | Gastroenterology | Jun 2029 |
| NCT07576959 | Vonoprazan | Phase 3 | HELICOBACTER PYLORI INFECTIONS | Infectious disease | Dec 2030 |
Cash of $185m on 2026-09-30; operating cash outflow about $21m a year; runway about 105 months at that burn, to Jun 2035; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Il-Yang Pharm. Carnot Laboratories AstraZeneca Cinclus Pharma Holding
Carnot Laboratories Cinclus Pharma Holding Madrigal Pharmaceuticals Biocodex Polaris Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.